Summary:

The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.

Description of Technology:

This technology includes an automated cell radiolabeling device that utilizes acoustophoresis microfluidic technology. The device streamlines the radiolabeling process by integrating cell washing and concentrating steps, which enhances reproducibility and standardization. This innovation simplifies the GMP (Good Manufacturing Practice) compliance for radiolabeling cells intended for human use. It also addresses the limitations of current manual methods that rely on centrifugation. The result is a benchtop system designed for clinical radio-pharmacies, ensuring efficient and reliable cell preparation for diagnostic and therapeutic applications.

Automated Acoustophoresis Device to Radio-Label & Isolate Cells for Immunotherapy and Isolated Cells for Immunotherapy Treatment

Potential Commercial Applications:

• Clinical radio-pharmacies for radiolabeled cell diagnostics
• Research institutions focused on cellular therapies and diagnostics
• Pharmaceutical companies developing radiolabeled therapeutics

Competitive Advantages:

• Fully automated process reduces manual intervention, increasing efficiency and consistency
• Micron-scale acoustophoresis technology enhances reproducibility and standardization of cell radiolabeling
• Streamlined GMP compliance simplifies regulatory processes for clinical applications
• Benchtop system